Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Plavix
Plavix 75 mg film-coated tablets Plavix 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-087943 · Präparat HOS-083591
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole
and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine,
carbamazepine, and efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): esomeprazole (HOS-087944) fluvoxamine (HOS-085908) fluoxetine (HOS-085946) moclobemide (HOS-087879) voriconazole (HOS-084524) fluconazole (HOS-087945) ticlopidine (HOS-087946) carbamazepine (HOS-085618) efavirenz (HOS-087947) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-14T12:15:00Z · SHA-256 1e6a9d1e2861882ccf51f6506686a24b3c88e112fad66a7a9333c6e88547592c · Passage 6adad8692c6fecb943bf126bdc5047021725d2d6aca1b2738e493857127bf04c · Zeichen 4217–4441 im Abschnitt
Wechselwirkungen · Iscover
Iscover 75 mg film-coated tablets Iscover 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-087998 · Präparat HOS-083599
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole
and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine,
carbamazepine, and efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912) esomeprazole (HOS-087944) fluvoxamine (HOS-085908) fluoxetine (HOS-085946) moclobemide (HOS-087879) voriconazole (HOS-084524) fluconazole (HOS-087945) ticlopidine (HOS-087946) carbamazepine (HOS-085618) efavirenz (HOS-087947)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-26T11:41:00Z · SHA-256 3fe5799ec5f9f1d2b848168c6cfaf56d702c6bce3141e7d7aa95ef81abbc8acc · Passage 6adad8692c6fecb943bf126bdc5047021725d2d6aca1b2738e493857127bf04c · Zeichen 4216–4440 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 58
HOS-116520 · Präparat HOS-094447
Clopidogrel Not studied. Co-administration of Co-administration of clopidogrel
clopidogrel with boosted PREZISTA is with boosted PREZISTA is not
expected to decrease clopidogrel active recommended. Use of other
metabolite plasma concentration, which antiplatelets not affected by CYP
may reduce the antiplatelet activity of inhibition or induction (e.g.
clopidogrel. prasugrel) is recommended.
Warfarin Not studied. Warfarin concentrations may It is recommended that the
be affected when co-administered with international normalised ratio
darunavir with low dose ritonavir. (INR) be monitored when warfarin
is combined with PREZISTA
co-administered with low dose
ritonavir.
ANTICONVULSANTS
Phenobarbital Not studied. Phenobarbital and phenytoin PREZISTA co-administered with
Phenytoin are expected to decrease plasma low dose ritonavir should not be
concentrations of darunavir and its used in combination with these
pharmacoenhancer. medicines.
(induction of CYP450 enzymes)
Carbamazepine carbamazepine AUC ↑ 45% No dose adjustment for
200 mg twice daily carbamazepine Cmin ↑ 54% PREZISTA/ritonavir is
carbamazepine Cmax ↑ 43% recommended. If there is a need to
darunavir AUC ↔ combine PREZISTA/ritonavir and
darunavir Cmin ↓ 15% carbamazepine, patients should be
darunavir Cmax ↔ monitored for potential
carbamazepine-related adverse
events. Carbamazepine
concentrations should be
monitored and its dose should be
titrated for adequate response.
Based upon the findings, the
carbamazepine dose may need to
be reduced by 25% to 50% in the
presence of PREZISTA/ritonavir.
Clonazepam Not studied. Co-administration of Clinical monitoring is
boosted PREZISTA with clonazepam recommended when
may increase concentrations of co-administering boosted
clonazepam. (CYP3A inhibition) PREZISTA with clonazepam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clopidogrel (HOS-087927) prasugrel (HOS-112066) warfarin (HOS-085950) ritonavir (HOS-084521) phenobarbital (HOS-085617) phenytoin (HOS-084531) carbamazepine (HOS-085618) clonazepam (HOS-116372)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 850ad5ed2985c0e66d0e474be614ba921c2559aea01cb8443674697805799b26 · Zeichen 25971–29352 im Abschnitt
Wechselwirkungen · Abraxane
Abraxane 5 mg/ml powder for dispersion for infusion. · Abschnitt 4.5 · PDF-Seite 9
HOS-117861 · Präparat HOS-094711
The metabolism of paclitaxel is catalysed, in part, by cytochrome P450 isoenzymes CYP2C8 and
CYP3A4 (see section 5.2). Therefore, in the absence of a PK drug-drug interaction study, caution
should be exercised when administering paclitaxel concomitantly with medicines known to inhibit
either CYP2C8 or CYP3A4 (e.g. ketoconazole and other imidazole antifungals, erythromycin,
fluoxetine, gemfibrozil, clopidogrel, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir)
because toxicity of paclitaxel may be increased due to higher paclitaxel exposure. Administering
paclitaxel concomitantly with medicines known to induce either CYP2C8 or CYP3A4 (e.g. rifampicin,
carbamazepine, phenytoin, efavirenz, nevirapine) is not recommended because efficacy may be
compromised because of lower paclitaxel exposures.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) ritonavir (HOS-084521) saquinavir (HOS-084522) indinavir (HOS-084518) nelfinavir (HOS-084520) carbamazepine (HOS-085618) phenytoin (HOS-084531) efavirenz (HOS-087947) nevirapine (HOS-088064) ketoconazole (HOS-084513) imidazole (HOS-117862) erythromycin (HOS-084514) fluoxetine (HOS-085946) gemfibrozil (HOS-088403) clopidogrel (HOS-087927)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-21T09:38:00Z · SHA-256 38c462aa5de60951dcb4be6132b86a26b536e6a1309509e0d2888dd17f8022aa · Passage f250f391b1f7f31d44e77cb1f0e86c8273e473bb0bc0fc63253f2b40dbd561f3 · Zeichen 0–813 im Abschnitt
Wechselwirkungen · Zyllt
Zyllt 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-121544 · Präparat HOS-095389
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole
and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine,
carbamazepine, and efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912) esomeprazole (HOS-087944) fluvoxamine (HOS-085908) fluoxetine (HOS-085946) moclobemide (HOS-087879) voriconazole (HOS-084524) fluconazole (HOS-087945) ticlopidine (HOS-087946) carbamazepine (HOS-085618) efavirenz (HOS-087947)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-14T12:07:00Z · SHA-256 f7bf5ef29f88fd676dd0507812419bb944fe4584c2c7bb6fde3ba14cc8084d6f · Passage 6adad8692c6fecb943bf126bdc5047021725d2d6aca1b2738e493857127bf04c · Zeichen 4156–4380 im Abschnitt
Wechselwirkungen · Grepid
Grepid 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-121586 · Präparat HOS-095397
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole
and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine,
carbamazepine, and efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945) ticlopidine (HOS-087946) carbamazepine (HOS-085618) efavirenz (HOS-087947) omeprazole (HOS-085912) esomeprazole (HOS-087944) fluvoxamine (HOS-085908) fluoxetine (HOS-085946) moclobemide (HOS-087879) voriconazole (HOS-084524)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-23T11:55:00Z · SHA-256 77bedbd07ba7109037505e509b70d3e89cce68a41661a537751991f1f383eb00 · Passage 6adad8692c6fecb943bf126bdc5047021725d2d6aca1b2738e493857127bf04c · Zeichen 4157–4381 im Abschnitt
Wechselwirkungen · Clopidogrel HCS
Clopidogrel HCS 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-124929 · Präparat HOS-095961
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole
and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine,
carbamazepine, and efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): omeprazole (HOS-085912) esomeprazole (HOS-087944) fluvoxamine (HOS-085908) fluoxetine (HOS-085946) moclobemide (HOS-087879) voriconazole (HOS-084524) fluconazole (HOS-087945) ticlopidine (HOS-087946) carbamazepine (HOS-085618) efavirenz (HOS-087947)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-08-01T02:00:00Z · SHA-256 ca426beb29f75b624527d51329ba517d85960904d2b54fe0bb1e1592d0525e34 · Passage 6adad8692c6fecb943bf126bdc5047021725d2d6aca1b2738e493857127bf04c · Zeichen 3573–3797 im Abschnitt
Wechselwirkungen · Xtandi
Xtandi - 40 mg soft capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-127857 · Präparat HOS-096479
• Analgesics (e.g. fentanyl, tramadol)
• Antibiotics (e.g. clarithromycin, doxycycline)
• Anticancer agents (e.g. cabazitaxel)
• Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid)
• Antipsychotics (e.g. haloperidol)
• Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel)
• Betablockers (e.g. bisoprolol, propranolol)
• Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil)
• Cardiac glycosides (e.g. digoxin)
• Corticosteroids (e.g. dexamethasone, prednisolone)
• HIV antivirals (e.g. indinavir, ritonavir)
• Hypnotics (e.g. diazepam, midazolam, zolpidem)
• Immunosuppressant (e.g. tacrolimus)
• Proton pump inhibitor (e.g. omeprazole)
• Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin)
• Thyroid agents (e.g. levothyroxine)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) felodipine (HOS-108908) nicardipine (HOS-090619) nifedipine (HOS-086289) verapamil (HOS-090602) digoxin (HOS-086172) dexamethasone (HOS-084535) primidone (HOS-090551) valproic acid (HOS-088515) haloperidol (HOS-085602) acenocoumarol (HOS-109456) warfarin (HOS-085950) clopidogrel (HOS-087927) bisoprolol (HOS-127867) propranolol (HOS-084529) calcium (HOS-085615) fentanyl (HOS-086196) tramadol (HOS-112871) clarithromycin (HOS-084517) doxycycline (HOS-127860) cabazitaxel (HOS-124028) carbamazepine (HOS-085618) clonazepam (HOS-116372) phenytoin (HOS-084531) prednisolone (HOS-086337) indinavir (HOS-084518) ritonavir (HOS-084521) diazepam (HOS-085904) midazolam (HOS-086167) zolpidem (HOS-086327) tacrolimus (HOS-085202) omeprazole (HOS-085912) atorvastatin (HOS-086304) simvastatin (HOS-086158) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 1a9d62c15c13d5c61581dad54a11c2cf2c5b042e25c19573444c32687d55e83b · Zeichen 3973–4850 im Abschnitt
Wechselwirkungen · Xtandi
Xtandi - 40 mg film-coated tablets Xtandi - 80 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 36
HOS-127925 · Präparat HOS-096479
• Analgesics (e.g. fentanyl, tramadol)
• Antibiotics (e.g. clarithromycin, doxycycline)
• Anticancer agents (e.g. cabazitaxel)
• Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid)
• Antipsychotics (e.g. haloperidol)
• Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel)
• Betablockers (e.g. bisoprolol, propranolol)
• Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil)
• Cardiac glycosides (e.g. digoxin)
• Corticosteroids (e.g. dexamethasone, prednisolone)
• HIV antivirals (e.g. indinavir, ritonavir)
• Hypnotics (e.g. diazepam, midazolam, zolpidem)
• Immunosuppressant (e.g. tacrolimus)
• Proton pump inhibitor (e.g. omeprazole)
• Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin)
• Thyroid agents (e.g. levothyroxine)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) primidone (HOS-090551) warfarin (HOS-085950) valproic acid (HOS-088515) haloperidol (HOS-085602) acenocoumarol (HOS-109456) fentanyl (HOS-086196) tramadol (HOS-112871) clarithromycin (HOS-084517) doxycycline (HOS-127860) cabazitaxel (HOS-124028) carbamazepine (HOS-085618) clonazepam (HOS-116372) clopidogrel (HOS-087927) bisoprolol (HOS-127867) propranolol (HOS-084529) calcium (HOS-085615) diltiazem (HOS-086288) felodipine (HOS-108908) nicardipine (HOS-090619) nifedipine (HOS-086289) verapamil (HOS-090602) digoxin (HOS-086172) dexamethasone (HOS-084535) prednisolone (HOS-086337) indinavir (HOS-084518) ritonavir (HOS-084521) diazepam (HOS-085904) midazolam (HOS-086167) zolpidem (HOS-086327) tacrolimus (HOS-085202) omeprazole (HOS-085912) atorvastatin (HOS-086304) simvastatin (HOS-086158) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-29T10:07:00Z · SHA-256 2bf5e532360d917a40a8717a4c2398563991ca5e2d824233a2adf92bb006bfb9 · Passage 1a9d62c15c13d5c61581dad54a11c2cf2c5b042e25c19573444c32687d55e83b · Zeichen 3974–4851 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-134492 · Präparat HOS-097580
Clopidogrel Not studied. Co-administration of Co-administration of clopidogrel
clopidogrel with boosted darunavir is with boosted darunavir is not
expected to decrease clopidogrel active recommended.
metabolite plasma concentration,
which may reduce the antiplatelet Use of other antiplatelets not
activity of clopidogrel. affected by CYP inhibition or
induction (e.g. prasugrel) is
recommended.
Warfarin Not studied. Warfarin concentrations It is recommended that the
may be affected when co-administered international normalised ratio (INR)
with darunavir with low dose ritonavir. be monitored when warfarin is
combined with darunavir co-
administered with low dose
ritonavir.
ANTICONVULSANTS
Phenobarbital Not studied. Phenobarbital and Darunavir co-administered with low
Phenytoin phenytoin are expected to decrease dose ritonavir should not be used in
plasma concentrations of darunavir and combination with these medicines.
its pharmacoenhancer.
(induction of CYP450 enzymes)
Carbamazepine carbamazepine AUC ↑ 45% No dose adjustment for
200 mg twice daily carbamazepine Cmin ↑ 54% darunavir/ritonavir is
carbamazepine Cmax ↑ 43% recommended. If there is a need to
darunavir AUC ↔ combine darunavir/ritonavir and
darunavir Cmin ↓ 15% carbamazepine, patients should be
darunavir Cmax ↔ monitored for potential
carbamazepine-related adverse
events. Carbamazepine
concentrations should be monitored
and its dose should be titrated for
adequate response.
Based upon the findings, the
carbamazepine dose may need to be
reduced by 25% to 50% in the
presence of darunavir/ritonavir.
Clonazepam Not studied. Co-administration of Clinical monitoring is
boosted darunavir with clonazepam recommended when co-
may increase concentrations of administering boosted darunavir
clonazepam. (CYP3A inhibition) with clonazepam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clopidogrel (HOS-087927) prasugrel (HOS-112066) warfarin (HOS-085950) ritonavir (HOS-084521) phenobarbital (HOS-085617) phenytoin (HOS-084531) carbamazepine (HOS-085618) clonazepam (HOS-116372)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 18f88a1538e549d8b6880998a637a7940712c9de8be51f9feea7646da83d20c9 · Zeichen 26132–29743 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-138482 · Präparat HOS-098200
Clopidogrel Based on theoretical Co-administration of Symtuza
considerations co-administration of with clopidogrel is not
Symtuza with clopidogrel is recommended. Use of other
expected to decrease clopidogrel antiplatelets not affected by CYP
active metabolite plasma inhibition or induction (e.g.
concentration, which may reduce prasugrel) is recommended (see
the antiplatelet activity of section 4.3).
clopidogrel.
Warfarin Based on theoretical It is recommended that the
considerations DRV/COBI may international normalised ratio
alter warfarin plasma (INR) be monitored when
concentrations. warfarin is co-administered with
Symtuza.
ANTICONVULSANTS
Carbamazepine Based on theoretical Co-administration of Symtuza
Phenobarbital considerations these and these anticonvulsants is
Phenytoin anticonvulsants are expected to contraindicated (see section 4.3).
decrease darunavir and/or
cobicistat and/or tenofovir
alafenamide plasma
concentrations.
(CYP3A and/or P-gp induction).
Oxcarbazepine Co-administration of Symtuza
with oxcarbazepine is not
recommended. Alternative
anticonvulsants should be
considered.
Clonazepam Based on theoretical considerations Clinical monitoring is
Symtuza is expected to increase recommended when
concentrations of clonazepam. co-administering Symtuza with
(inhibition of CYP3A) clonazepam.
ANTI-DEPRESSANTS
Herbal supplements Based on theoretical considerations Co-administration of
St. John’s Wort St. John’s Wort is expected to St. John’s Wort and Symtuza is
decrease darunavir and/or contraindicated (see section 4.3).
cobicistat and/or tenofovir
alafenamide plasma
concentrations.
(CYP3A and/or P-gp induction)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clopidogrel (HOS-087927) prasugrel (HOS-112066) warfarin (HOS-085950) carbamazepine (HOS-085618) phenobarbital (HOS-085617) phenytoin (HOS-084531) tenofovir (HOS-088083) oxcarbazepine (HOS-110224) clonazepam (HOS-116372)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 187c0fed160e40c7da0a4ce1c8b126337a2665df943610da374a786680424cda · Zeichen 11857–14725 im Abschnitt
Wechselwirkungen · Enzalutamide Viatris
Enzalutamide Viatris 40 mg film-coated tablets Enzalutamide Viatris 80 mg film-coated tablets Enzalutamide Viatris 160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-152525 · Präparat HOS-100781
Groups of medicinal products that can be affected include, but are not limited to:
• Analgesics (e.g. fentanyl, tramadol)
• Antibiotics (e.g. clarithromycin, doxycycline)
• Anticancer agents (e.g. cabazitaxel)
• Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid)
• Antipsychotics (e.g. haloperidol)
• Antithrombotics (e.g. acenocoumarol, warfarin, clopidogrel)
• Betablockers (e.g. bisoprolol, propranolol)
• Calcium channel blockers (e.g. diltiazem, felodipine, nicardipine, nifedipine, verapamil)
• Cardiac glycosides (e.g. digoxin)
• Corticosteroids (e.g. dexamethasone, prednisolone)
• HIV antivirals (e.g. indinavir, ritonavir)
• Hypnotics (e.g. diazepam, midazolam, zolpidem)
• Immunosuppressant (e.g. tacrolimus)
• Proton pump inhibitor (e.g. omeprazole)
• Statins metabolised by CYP3A4 (e.g. atorvastatin, simvastatin)
• Thyroid agents (e.g. levothyroxine)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): calcium (HOS-085615) diltiazem (HOS-086288) felodipine (HOS-108908) nicardipine (HOS-090619) nifedipine (HOS-086289) verapamil (HOS-090602) digoxin (HOS-086172) dexamethasone (HOS-084535) prednisolone (HOS-086337) indinavir (HOS-084518) ritonavir (HOS-084521) diazepam (HOS-085904) midazolam (HOS-086167) zolpidem (HOS-086327) tacrolimus (HOS-085202) omeprazole (HOS-085912) atorvastatin (HOS-086304) simvastatin (HOS-086158) levothyroxine (HOS-086339) clopidogrel (HOS-087927) bisoprolol (HOS-127867) propranolol (HOS-084529) fentanyl (HOS-086196) tramadol (HOS-112871) clarithromycin (HOS-084517) doxycycline (HOS-127860) cabazitaxel (HOS-124028) carbamazepine (HOS-085618) clonazepam (HOS-116372) phenytoin (HOS-084531) primidone (HOS-090551) valproic acid (HOS-088515) haloperidol (HOS-085602) acenocoumarol (HOS-109456) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-23T15:00:00Z · SHA-256 9ec2075aeb7a3bf9d945f1434168aa948ef3cdae81a1cefa92c76a3324997d49 · Passage bfc103097c88d7d8aeea8e7e62639ae12301bc9736ef551eb28e5ea67198b6ec · Zeichen 3904–4850 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.